An adaptive real-time intelligent system to enhance self-care of chronic disease (ARISES)

Diabetes mellitus is an increasingly prevalent chronic metabolic condition characterised by impaired glucose homeostasis and raised blood glucose levels (hyperglycaemia). Broadly categorised as either type 1 (T1DM) or type 2 diabetes (T2DM), people with diabetes are largely responsible for self-managing their blood glucose levels. Despite the development of diabetes technologies such as real time continuous glucose monitoring (RT-CGM), many individuals are frequently exposed to iatrogenic low blood glucose levels (hypoglycaemia). Severe hypoglycaemia is associated with an increased risk of recurrent hypoglycaemia, impaired symptomatic awareness of hypoglycaemia, and potentially death if left untreated. This thesis affirmed the existing clinical impact of severe hypoglycaemia and its recurrent risk in a six-month analysis of severe hypoglycaemia attended by the London Ambulance Service NHS Trust (LAS). Fewer incidents of severe hypoglycaemia observed in a date matched repeat analysis during the 2020 COVID-19 lockdown suggested improved self-management possibly motivated by a proximal fear of hospitalisation and improved structure at home. Finally, a 12-week randomised control trial demonstrating a significant difference in time spent in hypoglycaemia <3mmol/L, is the first study to prove the immediate provision of RT-CGM significantly reduces the risk of recurrent hypoglycaemia. Moreover, it highlighted the impact of socioeconomic disparity as a barrier to effective hypoglycaemia risk modification. This guided the design of an adaptive real time intelligent system to enhance self-care of chronic disease (ARISES) aimed to deliver therapeutic and lifestyle decision support for people with T1DM. The ARISES graphic user interface (GUI) design was a collaborative process conceived in a series of focus group meetings including people with T1DM. Finally, a 12-week observational study using RT-CGM, a physiological sensor wristband, and a mobile diary app, allowed for a sub-analysis identifying measurable physiological parameters associated with current and impending hypoglycaemia in people with T1DM.Open Acces

Cross-sectional analysis of emergency hypoglycaemia and outcome predictors among people with diabetes in an urban population

Out-of-hospital hypoglycaemia is a common complication for individuals with diabetes mellitus and represents a significant burden to emergency medical services (EMS). We aim to identify the factors associated with receiving parenteral treatment and hospital conveyance. We retrospectively analysed a 6-month data set of all London EMS hypoglycaemia. Individuals with a known diabetes diagnosis were included in our analysis and stratified as either having type 1 diabetes or type 2 diabetes. A total of 2862 incidents occurred within the area served by London Ambulance Service between January and June 2018. Fifty percent of incidents required parenteral treatment (intravenous glucose or intramuscular glucagon) and were conveyed to hospital. A higher arrival of blood glucose, intact consciousness and receiving oral glucose treatment were all negative predictors for requiring parenteral therapy. Forty-three percent of incidents were labelled as 'hypoglycaemia' by the EMS call handler, and greater odds of hospitalisation were observed among incidents that received parenteral treatment (OR 2.52 [95% CI 1.46, 4.33] p < 0.01) and individuals with type 2 diabetes (OR 2.67 [95% CI 1.52, 4.71] p < 0.01). Repeated callouts from 2% (n = 50) of individuals accounted for 10% (286) of all incidents attended, and 56.4% of individuals attended by EMS on more than one occasion had type 1 diabetes. Severe hypoglycaemia requiring emergency service attendance remains common, as does the requirement for parenteral therapy and conveyance to hospital. Early intervention, education and improved accessibility to risk prevention strategies may reduce the necessity for emergency parenteral treatment and hospitalisation, especially among individuals suffering from recurrent hypoglycaemia and high-risk individuals with type 2 diabetes. [Abstract copyright: © 2021 Diabetes UK.